Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
about
Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?Targeted therapies and immunotherapy in non-small-cell lung cancerPersonalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practiceEstablishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients.Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database.Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma.Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.A retrospective analysis of the clinicopathological and molecular characteristics of pulmonary blastoma.Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterationsNoninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing.ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.Discovery of a potent dual ALK and EGFR T790M inhibitor.Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancerEfficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC.Clinical and CT characteristics of surgically resected lung adenocarcinomas harboring ALK rearrangements or EGFR mutations.Disease flare after discontinuing gefitinib in a patient with lung adenocarcinoma and concomitant epithelial growth factor receptor mutation and anaplastic lymphoma kinase translocationALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma.Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas.Homogeneity and High Concordance of ALK Translocation in Primary Lung Adenocarcinoma and Paired Lymph Node Metastasis.Commentary on tumor heterogeneity.Reply to Chou et al 'Do significant TFE3 gene rearrangements occur in succinate dehydrogenase deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution' Mod Pathol 2017; in press.FLNa negatively regulated proliferation and metastasis in lung adenocarcinoma A549 cells via suppression of EGFR.A comparison of ALK gene rearrangement and ALK protein expression in primary lung carcinoma and matched metastasis.A comparison of ARMS-Plus and droplet digital PCR for detecting EGFR activating mutations in plasma.Longitudinal multi-parametric imaging in radiation oncology: boon or bane?The promise of multiparametric imaging in oncology: how do we move forward?A Convergence-Based Framework for Cancer Drug Resistance.Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations.Q58714451
P2860
Q26738390-EC6FC665-E4E9-46A8-812F-C62A55C4F430Q26738986-0C335FAA-433C-4838-96E8-3CE73C18D3DCQ28071903-DE7201D0-BC8C-49E5-A20D-0039268A1917Q33582635-3A182EB2-4123-4AA1-9902-6396BF89C0C0Q33648864-1F8202DE-E594-47ED-A4CB-C9A5FCA6C61BQ33730022-6515E2D3-F3D8-4E9B-834A-A4044D762B35Q36948934-A4870BDC-6490-42AE-8C93-0214DF3F608FQ37269159-3218A364-096E-4433-B80E-217615791DAEQ37413101-131ECE1F-9071-453E-9F69-749ABC9009E1Q37580410-12242657-0740-44A0-A51A-7A63E9245F33Q37662206-6673ECEF-A083-4AA6-8285-4C934B611C7AQ37662209-56FC1382-58BA-4991-8785-E84ED309497FQ37696243-710663FD-CDCF-42C5-A6EE-6B8753A6548DQ37698613-6028C18F-BC85-4868-BD96-1DC10A866EE5Q38671947-598D8EBA-62AF-4036-974F-D4EB5C950AEFQ38702793-81346528-B135-449E-950B-BB62F46D7558Q38828319-9323950E-02A0-4009-B884-13A4F8AE3FFAQ38846823-BEA03A7F-43E6-4F11-B95E-5F5FDA809CEDQ40518308-A34DA358-3E01-4854-BA0F-3AB95CD89E89Q40986813-6AA16D8C-35DF-4C41-8EC6-BDB58CAC98C2Q41037400-B6F9764C-7CE6-41EE-A16B-C84CC15479D3Q41233667-D6A30A7F-5C86-4578-9B17-37A701EAD176Q41475904-DE58FDC7-A818-404E-9841-A55374B8C75CQ42398711-4EA90608-2A21-427E-8983-6C621EDB4888Q46611738-28B8886C-C8DF-4801-A08A-62E54ADE472DQ47260594-CD054B8A-FD09-419A-AAF4-588BC76E637EQ48108243-87E7BF34-DFE7-4180-B50A-6F1F283932D0Q48505939-65F01BD7-1FBE-498F-A55D-502B0285C00CQ50452212-C2685D76-9B3B-4E1E-8FBB-91928FA71BBAQ50525080-A50A29E8-5D42-4DCD-9B92-EC8FC916ECB5Q53682041-16757DA2-2880-4092-9CC7-3D57B1D14D0DQ54981628-CB967BC0-1E32-44B9-8D65-A1CA9844ECB7Q58714451-340DA1B7-8F08-4116-8A20-90AD717574C5
P2860
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
@ast
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
@en
type
label
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
@ast
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
@en
prefLabel
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
@ast
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
@en
P2093
P2860
P356
P1476
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
@en
P2093
Caicun Zhou
Chunyan Wu
Dongmei Lin
Fred R Hirsch
Limou Zheng
Shannon Chuai
Weijing Cai
P2860
P304
P356
10.1200/JCO.2014.58.8293
P407
P577
2015-09-28T00:00:00Z